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Abstract
STEMI   is   part   of   the   acute   coronary   syndromes  world  which   is   one   of   the  most   common  
causes  of  death  in  the  world.  One  of  STEMI  treatment  is  percutaneous  coronary  intervention  (PCI)  
using  stents,  such  as  drug-­eluting  and  bare-­metal  stents.  These  stents  can  reduce  the  recurrence  
of  a  subsequent  heart  attack.  Three  articles  were   found   from  the  online  databases   then  critical  
appraisal  was  performed.  The  three  articles  have  ARR  range  of  0.3%  -­3.6%,  RRR  5%-­44,3%  and  
NNT  29-­333  patients.The   three  articles   stated   that   drug-­eluting   stents   compared   to  bare-­metal  
?????????????????????????????????????????????????????????????????????????????????????????????
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Perbandingan  Penggunaan  Drug-­Eluting  Stents  dan  Bare-­Metal  Stents  dalam  
Rekurensi  ST  Elevasi  Miokard  Infark
Abstrak  
STEMI   adalah   bagian   dari   sindrom   koroner   akut   yang   merupakan   salah   satu   penyebab  
kematian  tersering  di  dunia.  Salah  satu  terapi  STEMI  adalah  percutaneus  coronary   intervention  
(PCI)   menggunakan   stent   seperti   drug-­eluting   stents   serta   bare-­metal   stents   yang   dapat  
menurunkan   rekurensi   serangan   jantung   berikutnya.   Dari   pencarian   didapatkan   3   artikel   yang  
kemudian   ditelaah   kritis.   Ketiga   artikel  memiliki   rentang  ARR  0,3%-­3,6%,  RRR  5%-­44,3%  dan  
NNT  29-­333  pasien.  Ketiga  artikel  menyatakan  tidak  ada  perbedaan  bermakna  antara  penggunaan  
drug-­eluting  stents  dan  bare-­metal  stents  dalam  menurunkan  rekurensi  serangan  infark  miokard.
Kata  kunci:  STEMI,  drug  eluting  stents,  bare  metal  stents,  rekurensi,  infark  miokard
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Clinical  Scenario
Male,   58   years   old   came   to   the   Emergency  
Department  with  chest  pain.  His  chest  pain  started  
3  hours  before  admission.  The  pain  was  dull,  in  the  
center   of   the   chest,   and   radiates   to   the   left   arm.  
The   ECG   shows   ST   segment   elevation   in   leads  
I,   avL,   V1-­V6;;   and   LBBB.   The   laboratory   tests  
showed  increasing  CK-­MB  and  Troponin  T.  Patient  
was  diagnosed  with  acute  ST-­elevation  myocardial  
infarction.   Doctors   advise   patients   to   undergo  
percutaneous  coronary  intervention  (PCI)  with  Drug  
Eluting   Stent   (DES).   Patient’s   family   then   asked  
whether  PCI  with  DES  may  reduce  the  recurrence  
of  heart  attacks.
Introduction
Despite  the  widespread  use  of  ECG    changes  
to   characterize   patients   presenting   with   acute  
myocardial   infarction,   little   is   known   about  
recent   trends   in   the   incidence   rates,   treatment,  
and   outcomes   of   patients   admitted   for   acute  
??????????? ??????????? ???????? ?????????? ??????????
to   the   presence   of   ST-­segment   elevation.   The  
acute  coronary  syndrome  model  espoused  by  the  
American   College   of   Cardiology   places   unstable  
angina,   non   ST-­segment   elevation   myocardial  
infarction   (NSTEMI),   and   ST-­segment   elevation  
myocardial   infarction   (STEMI)   at   increasingly  
severe   points   along   a   disease   continuum.1,2  
Clinical  trial  and  registry  data  have  supported  this  
conceptual  model  by  showing  that  individuals  with  
NSTEMI   and   STEMI   have   differing   short   term  
prognoses  and  responses  to  therapies.3,4
STEMI   represents   one   end   of   a   spectrum   of  
related  conditions  called  acute  coronary  syndromes.  
The  underlying  common  pathophysiology  involves  
the   sudden   rupture   of   an   atheromatous   plaque  
(cholesterol-­rich   material)   within   the   wall   of  
a   coronary   artery.   This   ruptured   plaque   then  
stimulates   blood   clotting   (thrombosis)   within   the  
affected   coronary   artery.   Complete   obstruction   to  
?????? ?????? ??????? ?????????? ???????? ??????????
of  ST  segment  elevation  on  the  electrocardiogram  
?????????????????????????????????????????????????
??????????????????? ???????????????????????????????
which  becomes  complete  over  the  subsequent  12  
to  24  hours.  Although  the  incidence  of  STEMI  has  
been   declining   over   the   last   20   years,   it   varies  
between   regions   of   the   UK   and   still   averages  
around   750   cases   per   million   people   each   year.  
Over  the  last  30  years  inhospital  mortality  following  
STEMI   has   fallen   from   around   20%   to   less   than  
5%,  a  change   that  has  been  attributed   to  various  
factors,  including  improved  drug  therapy  and  speed  
of  access  to  effective  treatments.
Coronary   artery   bypass   grafting   (CABG)   has  
long  been  considered   the  standard  procedure   for  
revascularization  of  unprotected  left  main  coronary  
artery   (LMCA)   stenosis.5   DES   have   been   shown  
to   dramatically   reduce   the   rate   of   restenosis   and  
target   lesion   revascularization   (TLR)   compared  
with  bare-­metal  stents  (BMS).6,7  As  the  indications  
for  DES  have  expanded,  LMCA  stenting  has  been  
performed   more   frequently.   Recent   studies   have  
reported   positive   short-­   and   long-­term   outcomes  
for   PCI   with   DES   implantation   for   unprotected  
LMCA  disease.8  The  purpose  study  is  to  compare  
the  clinical  outcomes  after  implantation  of  DES  and  
BMS  in  STEMI  patients.
Clinical  Question
In  patient  with  STEMI,  does  treatment  with  DES  
compared  to  the  BMS  lead  to  recurrence  reduction  
of  myocardial  infarction?
Method
The   search   method   was   using   the   online  
databases  to  search  relevant  articles  .  The  search  
was   conducted   in   Pubmed®,   Sciencedirect®,  
Clinical   Key®,   and   Proquest®.   From   these   online  
databases,  we  were  searching  the  relevant  articles  
using  the  search  queries  (Table  1).  The  keywords  
that  were  used  in  the  searching  were  STEMI,  drug-­
eluting   stents,   bare-­metal   stents,   and   recurrent,  
these   keywords   and/or   other   related   terms   were  
conducted   in   the   search   queries.   From   these  
databases,   we   found   some   articles   that   relevant  
??? ???? ????????? ????????? ????? ???????? ??????????
???? ?????????? ????????? ??? ???? ???? ???????? ??????????
???? ??????? ????????? ?????????? ???? ?????????? ????
exclusion  criteria  are  shown  in  Figure  1.
The  articles  that  have  found  in  online  literature  
database  were  appraised  in  validity,  important,  and  
applicability.   The   articles   also   have   their   relevant  









(((((PCI[Title/Abstract])   OR   bare   metal   stent[Title/Abstract])   OR   stent[Title/
Abstract]))   AND   ((drug-­eluting[Title/Abstract])   OR   DES[Title/Abstract]))   AND  
((((ST-­segment[Title/Abstract])  OR  ST  elevation[Title/Abstract])  OR  STEMI[Title/
Abstract]))
Science  direct
TITLE-­ABSTR-­KEY((STEMI  or  ST  elevation  or  ST  segment  elevation)  AND  (drug-­
eluting  stent  or  DES))  and  TITLE-­ABSTR-­KEY((PCI  or  stent  or  bare  metal  stent)  
AND  (recurrent  or  restenosis))  
Proquest ab(STEMI  or  ST  elevation)  AND  ab((DES  OR  drug  eluting  stent))  AND  ab((PCI  OR  bare  metal  stent))  AND  ab((recurrent  OR  restenosis))
Clinical  Key ab(STEMI  or  ST  elevation)  AND  ab((DES  OR  drug  eluting  stent))  AND  ab((PCI  OR  bare  metal  stent))  AND  ab((recurrent  OR  restenosis))
Figure  1.  Flowcharts  of  the  Articles  Searching
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Kaltoft  et  al9 RCT 626 + + + + + + + 2b
Stone  et  al10 RCT 3006 + -­ + + + + + 2b
Palmieri  et  al11 RCT 453 + -­ N/A + + + + 2b
Results
From   the   online   databases,   we   found   nine  
????????? ?????? ????????? ???? ?????????? ???? ?????????
articles.  This  search  were  conducted   in  26th  June  
2013.   After   reading   the   full   text   from   those   nine  
articles,  we  only  found  three  articles  that  were  useful.  
These  three  articles  were  appraised  from  its  validity  
and  relevance.  Those  three  articles  were  Kaltoft  A  et  
al9,  Stone  GW  et  al10,  and  Palmieri  C  et  al11.  
??? ???? ????? ???????? ????????? et   al9),   a   total   of  
626   STEMI   patients   in   randomized   so   that   there  
were  313  patients  in  DES  group  and  313  patients  
in  BMS  group.  Then  after   3   years   of   follow-­up   is  
done  then  there  were  9  patients  in  the  DES  group  
had  a  myocardial  infarction  (4.2%)  and  there  were  
15   patients   in   the   BMS   group   had   a   myocardial  
infarction  (5.4%)  with  p  =  0.58.9
In   the   second   article   (Stone   et   al10),   a   total  
of  3006  STEMI  patients,  749  patients   in   the  BMS  
group  and  2257  patients  in  PES  group.  After  follow-­
up  of  24  months  43  patients   in  BMS  group  had  a  
myocardial   infarction   (6%)   and   123   patients   had  
myocardial   infarction   PES   group   (5.7%)   with   a  
value  of  p  =  0.73.10
In  the  third  article  (Palmieri  et  al11),  a  total  of  453  
STEMI  patients  were  randomized  so  that  there  were  
176   patients   in   the  BMS  groups   and   277   patients  
in   DES   group.  After   follow-­up   of   26  months   there  
were  14  patients  in  the  BMS  group  had  a  myocardial  
infarction  (7.9%)  and  12  patients  in  the  DES  group  
had  a  myocardial  infarction  (4.3%)  with  p  =  0.09.11
Discussion
?????????????????????????????et  al),  the  number  of  
patients   large   enough,   long   enough   follow-­up   is  
done  and  complete.  From  the  results  of  the  statistical  
calculations   it  can  be  seen  that  the  Absolute  Risk  
Reduction  (ARR)  in  this  article  is  only  1.9%  which  
means   that   the   risk   of   myocardial   infarction   was  
reduced   only   1.9%   in   the   DES   group   compared  
to   the   BMS   group.   The   Relative   Risk   Reduction  
(RRR)  is  40%  means  that  using  DES  is  40%  better  
than  BMS  in  reducing  the  recurrency  of  myocardial  
infarction.  The  results  of  Number  Needed  to  Treat  
(NNT)   is   53   pts,   which   means   to   prevent   one  
myocardial  infarction  patients  required  intervention/  
treatment  at  53  patients.  And  on  the  calculation  of  
???? ????????????????????????????????????????????
0.054,  in  the  range  of  95%  CI  past  zero  so  that  the  
???????????????????????????????????????????????????
?????????????????????????????
In  the  second  article  (Stone  et  al),  the  number  
of  patients   large  enough  and   long  enough   follow-­
up   is  done  and  complete.  From  the  results  of   the  
statistical   calculations   showed   ARR   0.3%   which  
means   that   the   risk   of   myocardial   infarction   in  
patients   with   DES   group   only   decreased   0.3%  
compared   to   the  BMS  group.  RRR   is   5%  means  
DES  is  5%  better  than  BMS.  NNT  in  this  article  is  
333  pts,  which  means   to  prevent   one  myocardial  
infarction  patients  required   intervention/   treatment  
at  333  patients.  The  yield  on  the  95%  CI  is  -­0.018  
to  0.019,  the  result  is  zero  through  the  use  of  DES  
Note:  (+)  :  +  stated  clearly  in  the  article,  -­  not  stated  clearly  in  the  article,  N/A  not  available
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compared  with  BMS.
In  the  third  article  (Palmieri  et  al),  the  number  
of   patients   who   use   large   enough,   follow   up  
???????????? ????? ???? ?????????? ?????? ????????????
statistics   showed   a   3.6%  ARR,  which  means   the  
use  of  DES   is  only  3.6%  reduces   the  occurrence  
of  myocardial  infarction  compared  with  BMS.  RRR  
is   44,3%  means   that   using   DES   is   44,3%   better  
than   BMS.   Calculation   results   of   NNT   is   29   pts  
which  means  to  prevent  one  myocardial  infarction  
patients   required   intervention   /   treatment   at   29  
?????????? ???? ??? ???????? ????????? ??????? ???????
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difference   of   using   drug-­eluting   stents   compared  
to   the   bare-­metal   stents   in   reducing   recurrency  
of  heart  attack  or  myocardial   infarction  in  patients  
with  ST-­elevation  myocardial   infarction.  From   this  
result,  the  drug-­eluting  stents  have  slight  reduction  
in  recurrent  of  myocardial  infarction.  Despite  of  this,  
the  bare-­metal  stents  would  have  be  the  choice  in  
treatment   of   ST-­elevation   myocardial   infarction  
than   drug-­eluting   stents   because   the   cost   was  
more   expensive   in   the   use   of   drug-­eluting   stents  
compared   to   the   bare-­metal   stents   and   it   didn’t  
????????????????????????????????
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